THE FAMILY OF HUMAN T-LYMPHOTROPIC RETROVIRUSES CALLED HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS (HTLV): THEIR ROLE IN LYMPHOID MALIGNANCIES AND LYMPHOSUPPRESSIVE DISORDERS (AIDS)

Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

THE FAMILY OF HUMAN T-LYMPHOTROPIC RETROVIRUSES CALLED HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS (HTLV): THEIR ROLE IN LYMPHOID MALIGNANCIES AND LYMPHOSUPPRESSIVE DISORDERS (AIDS)

Bristol-Myers Cancer Symp; 7:183-202 1985. Unique Identifier : AIDSLINE ICDB/87627485
Gallo RC; Ratner L; Popovic M; Salahuddin SZ; Sarngadharan MG; Wong-Staal F; Shaw G; Hahn B; Reitz M; Robert-Guroff M; et al; Lab. of Tumor Cell Biology, NCI, Bethesda, MD

Abstract: Studies illustrating the disparate effects of the various human T cell leukemia (lymphotropic) viruses (HTLVs) are reviewed together with recent investigations concerning acquired immune deficiency syndrome (AIDS) under the following headings: transformation of T cells by HTLV-I and HTLV-II; possible mechanisms of HTLV-I- and HTLV-II-induced transformation; HTLV-III - the cause of AIDS; molecular mechanisms of HTLV-III - biological effects; and future directions. Work to date on HTLV-I, -II, and -III has clearly delineated two directions that future research efforts should take: prevention and treatment of the diseases known to be associated with family members and identification of additional family members that may play a role in other human diseases. Concerning treatment, the proliferative disease caused by HTLV-I (adult T-cell leukemia) and the cytopathic one caused by HTLV-III (AIDS) will clearly require different therapeutic approaches. Studies to date have suggested that HTLV-I, while initiating the transformation of T cells and thereby the process leading to frank malignancy, may not be necessary for the maintenance of the transformed state. Thus, treatment regimens should not necessarily be directed toward viral proteins. In the case of AIDS, on the other hand, patients appear to be viremic. Therefore, therapeutic regimens aimed at inhibiting HTLV-III replication via its reverse transcriptase may be effective in some stages of disease. Preventative measures for all HTLV family member infections have focused on vaccines. (68 Refs)

Keywords: Acquired Immunodeficiency Syndrome/*GENETICS Cell Survival Cell Transformation, Neoplastic Cell Transformation, Viral DNA, Viral/GENETICS Human HLA Antigens/GENETICS HTLV-BLV Infections/*GENETICS HTLV-BLV Viruses/*GENETICS Leukemia, Hairy Cell/*GENETICS Oncogenes MEETING PAPER

870228
M8720251

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .